The Short Answer: Almost Never

Ask an institutional investor to sign a non-disclosure agreement before a first meeting and you get a polite no. Ask twice and the meeting quietly stops getting rescheduled. This is close to universal among venture funds and most active angels, and it is not a judgment about your invention.

It is also not a reason to panic. What you need to share in a first meeting and what could actually hurt you if it leaked are two different sets, and most founders conflate them. Once you separate them, pitching without an NDA stops feeling like undressing in public.

Why They Refuse

The reasons are structural, and understanding them removes most of the sting.

  • Volume. An active fund reviews well over a thousand opportunities a year, many clustered in the same three or four themes. Signing with every one would create a web of overlapping obligations nobody could track, let alone honor.
  • Contamination risk. If a fund signs your NDA and later backs a company in the same space, you have a plausible claim and they have a lawsuit. Their downside is unbounded; their upside is a single meeting they can skip.
  • Portfolio conflicts. They may already own a competitor you have never heard of, and signing before hearing your pitch would breach duties to that company.
  • Diligence needs sharing. Investors show deals to co-investors, technical advisors, and sometimes limited partners. A broad NDA blocks the exact process that leads to a check.
  • Signal. Fair or not, a founder who leads with an NDA reads as someone who thinks the idea is the asset. Investors think execution is the asset, so the request becomes evidence against you.

When Investors Actually Do Sign

The blanket "investors never sign" advice is overstated. Knowing the real cases keeps you from asking at the wrong moment or failing to ask at the right one.

Deep diligence after a term sheet. Once a deal is live and you are opening source code, unfiled patent drafts, clinical data, supplier contracts, or a full costed BOM, an agreement covering that material is normal and routinely signed. This is the moment to ask, not the first call. Structure the disclosure to match, along the lines of an investor data room with staged access.

Corporate and strategic investors. A venture arm attached to an operating business behaves differently from a financial fund. They have their own products and lawyers, and mutual NDAs are standard practice. Ask, and expect their paper rather than yours.

Individual angels and family offices. Less deal flow, less institutional policy, and often willing. Worth asking only when the material justifies it.

Genuinely secret technical content. A formulation, a process parameter set, an algorithm you intend to keep as a trade secret. Most reasonable investors will sign something narrow covering that specific disclosure, and you should not show it otherwise.

How to Protect the Idea Without a Signature

File first, then pitch. The single most effective move. A provisional application establishes a priority date for a modest fee plus attorney time and buys twelve months to convert. Once it is on file, disclosure is no longer a race condition, and "patent pending" answers the confidentiality question better than any agreement. The mechanics are in how to file a provisional patent application.

Separate the what from the how. An investor needs the problem, the market, why current solutions fail, what your product does for the user, traction, unit economics, and why this team wins. None of that requires teaching anyone to build it. Enabling detail, meaning specific mechanism, tolerances, materials, firmware architecture, or supplier list, belongs in diligence. A pitch that withholds it is not evasive; it is normal.

Watch the disclosure clock. A private pitch is generally not a public disclosure, but that is not a boundary you want to litigate, and filing first also protects rights in jurisdictions with absolute novelty and no grace period. The traps are in public disclosure before filing a patent.

Decide what will never be patented. Some know-how is better kept quiet than published in an application, and that choice changes what goes in the deck and what never leaves the building; the tradeoff is in trade secret versus patent.

Keep records and diligence the investor. Dated decks with version numbers and an email trail for every send cost nothing and become your timeline if a dispute arises. Reputation is the real enforcement mechanism here, so ask other founders in the portfolio, and specifically ask founders they passed on. An investor with a history of funding a copycat is known, and the community talks.

Investors Are Not Vendors, and the Rules Are Opposite

This distinction saves founders from the worst version of this mistake: concluding that because investors do not sign NDAs, nobody signs NDAs.

A contract manufacturer, a design firm, a mold maker, a packaging supplier, a firmware contractor: all of them will sign, all of them should, and a refusal is a genuine red flag. Their relationship with you is different in kind. They receive enabling detail, complete drawings, full bills of materials, and tooling geometry, and they are commercially capable of building the product themselves. An investor receives a story.

For overseas manufacturing the bar is higher, because a standard US-style NDA is often unenforceable where it matters. What works is an agreement under the manufacturer's own jurisdiction with non-use and non-circumvention terms and real damages, as explained in the NNN agreement for China manufacturing. Use the right instrument in the right relationship, and read NDAs for inventors for where each one holds.

The Real Protection Is Being Ahead

Suppose the worst case happens and a fund passes, then backs a team building something similar. What did they take? A market thesis. Not your supplier relationships, not the eighteen months of failed prototypes that taught you which geometry works, not your regulatory clearance, tooling, channel, or team.

Ideas leak constantly and almost nothing happens, because the gap between knowing what to build and being able to build it is where the value lives. The founders who get hurt are the ones who spent a year protecting an idea instead of executing on it, and reached the market second anyway.

Practically: file the provisional, pitch the value rather than the mechanism, keep the deepest know-how for diligence under a narrow agreement, and move fast enough that a copy is always a year behind. The general version of the same instinct is in how to talk about your invention idea without getting it stolen.

Get the Protection Sequence Right

Projects House works with founders on the order of operations before a raise: what to file and when, which technical material belongs in the deck versus the data room, and which suppliers need what agreement before they see a drawing. Send your situation through our contact form.